Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Income from Continuing Operations (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Income from Continuing Operations for 8 consecutive years, with 29815000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Income from Continuing Operations rose 18.75% year-over-year to 29815000.0, compared with a TTM value of 95095000.0 through Sep 2025, down 467.43%, and an annual FY2024 reading of 37450000.0, up 62.98% over the prior year.
  • Income from Continuing Operations was 29815000.0 for Q3 2025 at X4 Pharmaceuticals, down from 25741000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 90833000.0 in Q2 2024 and bottomed at 55712000.0 in Q2 2023.
  • Average Income from Continuing Operations over 5 years is 19813368.42, with a median of 21965000.0 recorded in 2022.
  • Peak annual rise in Income from Continuing Operations hit 263.04% in 2024, while the deepest fall reached 1492.02% in 2024.
  • Year by year, Income from Continuing Operations stood at 30207000.0 in 2021, then increased by 3.65% to 29104000.0 in 2022, then skyrocketed by 34.27% to 19130000.0 in 2023, then crashed by 108.16% to 39821000.0 in 2024, then grew by 25.13% to 29815000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for XFOR at 29815000.0 in Q3 2025, 25741000.0 in Q2 2025, and 282000.0 in Q1 2025.